Goodwill and Other Intangible Assets

6 Months Ended

Jun. 30, 2017

Goodwill and Other Intangible Assets

7.Goodwill and Other Intangible Assets

The following table sets forth the changes in the carrying amount of goodwill for the six months ended June 30, 2017 (in millions):

Balance at December 31, 2016	$	130.6
Goodwill acquired during the period	32.2
Foreign currency effect	2.6

Balance at June 30, 2017	$	165.4

The following is a summary of intangible assets (in millions):

	June 30, 2017							December 31, 2016
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Existing technology and related patents	$	190.0	$	(125.8	)	$	64.2	$	169.0	$	(113.9	)	$	55.1
Customer relationships	33.9		(10.4		)	23.5		20.0		(7.9		)	12.1
Non compete contracts	1.8		(1.3		)	0.5		1.8		(1.1		)	0.7
Trade names	4.0		(0.6		)	3.4		1.6		(0.4		)	1.2

Intangible assets subject to amortization	229.7		(138.1		)	91.6		192.4		(123.3		)	69.1
In-process research and development	0.6		—			0.6		0.6		—			0.6

Intangible assets	$	230.3	$	(138.1	)	$	92.2	$	193.0	$	(123.3	)	$	69.7

For the three months ended June 30, 2017 and 2016, the Company recorded amortization expense of $7.5 million and $5.4 million, respectively, related to intangible assets subject to amortization. For the six months ended June 30, 2017 and 2016, the Company recorded amortization expense of $14.4 million and $10.8 million, respectively, related to intangible assets subject to amortization.

The goodwill and intangibles acquired in the first quarter of 2017 related primarily to the Hysitron and Luxendo acquisitions. Please see Note 2—Acquisitions, for additional details on the goodwill and intangibles acquired.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details